Endothelial superoxide dismutase 2 is decreased in sickle cell disease and regulates fibronectin processing. Issue 2 (17th February 2022)

• Record Type: Journal Article
• Authors: Dosunmu-Ogunbi, Atinuke; Yuan, Shuai; Shiwarski, Daniel J; Tashman, Joshua W; Reynolds, Michael; Feinberg, Adam; Novelli, Enrico M; Shiva, Sruti; Straub, Adam C
• Is Part Of: Function. Volume 3:Issue 2(2022)
• Publication Date: 2022-02-17
• Subjects: fibronectin -- sickle cell -- sod2 -- endothelium -- redox -- reactive oxygen species -- mitochondria; Cell biology -- Periodicals; Medicine -- Periodicals; 616
• DOI: 10.1093/function/zqac005
• Languages: English
• ISSNs: 2633-8823

Abstract

Abstract: Sickle cell disease (SCD) is a genetic red blood cell disorder characterized by increased reactive oxygen species (ROS) and a concordant reduction in antioxidant capacity in the endothelium. Superoxide dismutase 2 (SOD2) is a mitochondrial-localized enzyme that catalyzes the dismutation of superoxide to hydrogen peroxide. Decreased peripheral blood expression of SOD2 is correlated with increased hemolysis and cardiomyopathy in SCD. Here, we report for the first time that endothelial cells exhibit reduced SOD2 protein expression in the pulmonary endothelium of SCD patients. To investigate the impact of decreased SOD2 expression in the endothelium, SOD2 was knocked down in human pulmonary microvascular endothelial cells (hPMVECs). We found that SOD2 deficiency in hPMVECs results in endothelial cell dysfunction, including reduced cellular adhesion, diminished migration, integrin protein dysregulation, and disruption of permeability. Furthermore, we uncover that SOD2 mediates changes in endothelial cell function via processing of fibronectin through its inability to facilitate dimerization. These results demonstrate that endothelial cells are deficient in SOD2 expression in SCD patients and suggest a novel pathway for SOD2 in regulating fibronectin processing. Graphical Abstract: